Loading viewer...
conference
Format: PDF conference
Nektar Therapeutics presents its biopharmaceutical pipeline and growth strategy at the 2017 JP Morgan Healthcare Conference. The presentation outlines proprietary drug candidates including NKTR-181, NKTR-214, NKTR-358, and NKTR-262, with projected annual revenue of $375-450M by 2021, supported by integrated R&D and manufacturing capabilities.
investor_presentation
31 Pages
conference
13 Pages
Veronafiere